Short answer
Tarsus Pharmaceuticals, Inc. (TARS) filed its Q3 2025 10-Q quarterly report on Nov 4, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $119M (up 146.7% year over year) with net income of −$13M.
Q3 2025 key financials · XBRL
- Revenue
- $119M
- +146.7% YoY · +15.6% QoQ
- Net income
- −$13M
- +46.3% YoY · +38.1% QoQ
- Operating margin
- -12.2%
- EPS (diluted)
- −$0.29
- +50.8% YoY · +38.3% QoQ
Source: XBRL data from the Tarsus Pharmaceuticals, Inc. (TARS) Q3 2025 10-Q on SEC EDGAR. USD.
Tarsus Pharmaceuticals, Inc. Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- New cybersecurity risk: increased threat from geopolitical tensions, including Russia-Ukraine conflict and Middle East unrest potentially disrupting IT systems
- Most updated risk: net loss narrowed to $12.6M Q3 2025 vs $23.4M Q3 2024, deficit grew to $418.3M as of Sept 30, 2025 reflecting ongoing operating losses
- Most impactful legal risk: potential significant product liability claims on XDEMVY with possibly inadequate insurance coverage for substantial liabilities
- Near-term operational risk: reliance on third-party CROs and CMOs critical; failure or delay in vendor services could extend clinical trials or delay commercialization
- Financial risk: exposure to inflation and geopolitical inflation pressure increasing operating expenses and impacting supply chain and distributor financial health
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Tarsus Pharmaceuticals, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.